Merck & Co Inc (NASDAQ:MRK) and Orion Corporation announced a global development and commercialization agreement for Orion’s ODM-208 and other drugs targeting cytochrome…
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the closing of an exclusive license agreement